Analysis of JAK1 and JAK2 promoter region methylation in CAD patients and control subjects also revealed lower methylation levels (Fig. 19), below 5% in both the genes; however it was significantly different in CAD patients as compared to the controls. This evidence concerns the gene JAK2 and coronary artery disorder.